SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Q2 2018 Earnings Conference Call August 7, 2018 4:30 PM ET Executives Willie Quinn – Chief Financial Officer and Sen
Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Basic Materials, Consumer Goods and Financials sectors led shares lower. At the close in...
The pharma/biotech sector has been struggling so far in 2018. The sector is plagued by several factors, which include drug pricing issues, declining sales of legacy products and...
On the Q118 conference call, Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) provided an update of its ongoing vecabrutinib Phase Ib/II trial. The study is continuing to enrol the 50mg...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Sell||Sell||Sell||Strong Sell||Strong Sell|
|Technical Indicators||Strong Buy||Strong Buy||BUY||Strong Sell||Strong Sell|
|Summary||Neutral||Neutral||Neutral||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Falling Three Methods||1W||1||Sep 09, 2018|
|Doji Star Bearish||30||1||Sep 18, 2018 03:00PM|
|Bullish Engulfing||1M||2||Jul 18|
|Deliberation Bearish||15||2||Sep 18, 2018 03:00PM|
|Doji Star Bearish||15||2||Sep 18, 2018 03:00PM|
|Bank Of Baroda||116.35||119.00||110.15||+3.25||+2.87%||117.57M||05:59:21|
|Tata Steel Ltd||621.20||630.80||617.40||+8.45||+1.38%||10.12M||05:59:18|
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$2000||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||$250||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.